These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23400695)

  • 1. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
    Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic and pharmacodynamic study on amrubicin and amrubicinol in Japanese patients with lung cancer.
    Makino Y; Yamamoto N; Sato H; Ando R; Goto Y; Tanai C; Asahina H; Nokihara H; Sekine I; Kunitoh H; Ohe Y; Sugiyama E; Yokote N; Tamura T; Yamamoto H
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):861-9. PubMed ID: 22042514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells.
    Hira A; Watanabe H; Maeda Y; Yokoo K; Sanematsu E; Fujii J; Sasaki J; Hamada A; Saito H
    Biochem Pharmacol; 2008 Feb; 75(4):973-80. PubMed ID: 18054347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration of amrubicinol in plateau phase in patients treated for 3 days with amrubicin is correlated with hematological toxicities.
    Kimura T; Kudoh S; Mitsuoka S; Yoshimura N; Tanaka H; Asai K; Kyoh S; Tochino Y; Umekawa K; Hirata K
    Anticancer Drugs; 2009 Jul; 20(6):513-8. PubMed ID: 19352172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
    Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
    Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of amrubicin, a synthetic 9-aminoanthracycline, in patients with refractory or relapsed lung cancer.
    Okamoto I; Hamada A; Matsunaga Y; Sasaki J; Fujii S; Uramoto H; Yamagata H; Mori I; Kishi H; Semba H; Saito H
    Cancer Chemother Pharmacol; 2006 Feb; 57(3):282-8. PubMed ID: 16028099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
    Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
    J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
    Maison-Blanche P; Vermorken JB; Goksel T; Machiels JP; Agarwala S; Rottey S; Daugaard G; Volovat C; Scheulen M; Sengeløv L; Grecea D; Eniu A; Jäger E; Meiri E; Cascinu S; Strumberg D; Demir G; Clemens M; Pinotti G; Nardi M; Guthrie T; Boelle E; Magherini E
    J Cardiovasc Pharmacol; 2013 Jun; 61(6):495-504. PubMed ID: 23429593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetic study of amrubicin in a case of small lung cancer on hemodialysis].
    Ohsawa M; Demizu M; Chihara S; Ueda H; Igarashi T; Tomiyama N; Nakashima Y; Hosoi K; Min K
    Gan To Kagaku Ryoho; 2009 Aug; 36(8):1311-4. PubMed ID: 19692770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer.
    Munster PN; Rubin EH; Van Belle S; Friedman E; Patterson JK; Van Dyck K; Li X; Comisar W; Chodakewitz JA; Wagner JA; Iwamoto M
    Clin Cancer Res; 2009 Nov; 15(22):7077-84. PubMed ID: 19887475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
    Maison-Blanche P; Dakhil S; Baron A; Rottey S; Millard F; Daugaard G; Machiels JP; Conkright W; Sharma S; Soetekouw PM; Yachnin J; Sengeløv L; Van Veldhuizen P; Agarwala SS; Sémiond D; Chadjaa M; Shen L; Wade JL
    Cancer Chemother Pharmacol; 2014 Jun; 73(6):1241-52. PubMed ID: 24718982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1067-73. PubMed ID: 9849587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline, and its active metabolite amrubicinol in P388 murine leukemia cells.
    Yamaoka T; Hanada M; Ichii S; Morisada S; Noguchi T; Yanagi Y
    Jpn J Cancer Res; 1999 Jun; 90(6):685-90. PubMed ID: 10429662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
    Burke JM; van der Jagt RH; Flinn IW; Craig MD; Chen L; Morganroth J; Munteanu MC; MacDonald DA
    Cancer Chemother Pharmacol; 2015 Jul; 76(1):211-6. PubMed ID: 26006703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.
    Bendell JC; Patel MR; Yoshida K; Seraj J; Weaver R; Lemech C; Todaro TG; Pant S; Arkenau HT
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1275-83. PubMed ID: 27151157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Literature review and pilot studies of the effect of QT correction formulas on reported beta2-agonist-induced QTc prolongation.
    Milic M; Bao X; Rizos D; Liu F; Ziegler MG
    Clin Ther; 2006 Apr; 28(4):582-90. PubMed ID: 16750469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Jpn J Cancer Res; 1998 Oct; 89(10):1061-6. PubMed ID: 9849586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.